FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808364235> ?p ?o ?g. }

• W2808364235 endingPage "2182" @default.
• W2808364235 startingPage "2175" @default.
• W2808364235 abstract "Background: The aim of this study was to explore whether postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy differ from healthy postmenopausal women in their response to the same aerobic + resistance training. Methods: The participants were separated into two groups: postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy for an average of 20 months (18 women) and healthy postmenopausal women (24 women). We assessed aerobic capacity (predicted maximum oxygen uptake (VO2max) and maximum running velocity test (Vmax)) through a walking test, upper and lower body muscle strength using an estimated one-repetition maximum test, and body composition by dual-energy X-ray absorptiometry at baseline and at three, six, and nine months, respectively. The exercise program was performed three times/week over nine months and consisted of 40 min of machine-based strength training (seated cable row, bench press, leg extension, leg press, and leg curl, as well as bridge, abdominal, and standard plank exercises) followed by 30 min of treadmill walking. Analysis of variance (ANOVA) with repeated measures was used to compare the groups over time. Results: Postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy and healthy postmenopausal women presented similar improvements in estimated lower body strength, predicted VO2max and Vmax, and body fat mass. For maximal upper body strength, there was a significant group x time interaction after six months of training (p = 0.01). The healthy postmenopausal women presented a significant increase in upper body strength after six months, while postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy demonstrated an improvement only at nine months of training. The breast cancer survivors undergoing aromatase inhibitor therapy presented increased lean mass while healthy postmenopausal women maintained values over time (Breast cancer: 33.7 ± 3.9(Pre) vs. 34.1 ± 3.4 kg (Post) and healthy women: 36.4 ± 5.1 (Pre) vs. 36.4 ± 5.0 kg (Post), p = 0.004). Conclusion: Our findings suggest that postmenopausal women undergoing aromatase inhibitor therapy for breast cancer demonstrated adaptations and similar trainability to the same regimen of resistance + aerobic training as healthy postmenopausal women. Implications for Rehabilitation Combined exercise program (aerobic plus resistance) is an important non-pharmacological strategies to improve strength, aerobic capacity, and body composition in breast cancer survivors undergoing aromatase inhibitor therapy. Furthermore, it is important to highlight that the time of intervention seems to influence the upper body strength response in this population. This study showed that trainers and other specialists do not need to modify the prescription of exercise related to healthy women, since the combined exercise program induced similar benefits in strength, aerobic capacity, and body composition in postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy and healthy postmenopausal women." @default.
• W2808364235 created "2018-06-21" @default.
• W2808364235 creator A5013031954 @default.
• W2808364235 creator A5033101354 @default.
• W2808364235 creator A5036105904 @default.
• W2808364235 creator A5040566189 @default.
• W2808364235 creator A5052382720 @default.
• W2808364235 creator A5076701726 @default.
• W2808364235 creator A5078267582 @default.
• W2808364235 creator A5084740062 @default.
• W2808364235 date "2018-04-12" @default.
• W2808364235 modified "2023-10-01" @default.
• W2808364235 title "Comparing exercise responses to aerobic plus resistance training between postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy and healthy women" @default.
• W2808364235 cites W1499602734 @default.
• W2808364235 cites W1602521239 @default.
• W2808364235 cites W1973931842 @default.
• W2808364235 cites W1980501379 @default.
• W2808364235 cites W1989020722 @default.
• W2808364235 cites W1990718894 @default.
• W2808364235 cites W1995865792 @default.
• W2808364235 cites W2009250017 @default.
• W2808364235 cites W2027894791 @default.
• W2808364235 cites W2039471900 @default.
• W2808364235 cites W2044634506 @default.
• W2808364235 cites W2044987966 @default.
• W2808364235 cites W2045462605 @default.
• W2808364235 cites W2045669956 @default.
• W2808364235 cites W2047264451 @default.
• W2808364235 cites W2087235275 @default.
• W2808364235 cites W2090705790 @default.
• W2808364235 cites W2096528264 @default.
• W2808364235 cites W2104442968 @default.
• W2808364235 cites W2112780046 @default.
• W2808364235 cites W2137691798 @default.
• W2808364235 cites W2142534216 @default.
• W2808364235 cites W2144536165 @default.
• W2808364235 cites W2149568734 @default.
• W2808364235 cites W2149615486 @default.
• W2808364235 cites W2152427545 @default.
• W2808364235 cites W2153143103 @default.
• W2808364235 cites W2172359919 @default.
• W2808364235 cites W2213143129 @default.
• W2808364235 cites W2214665719 @default.
• W2808364235 cites W2288959164 @default.
• W2808364235 cites W2336721677 @default.
• W2808364235 cites W2339595123 @default.
• W2808364235 cites W2477544715 @default.
• W2808364235 cites W2557299371 @default.
• W2808364235 cites W2565372774 @default.
• W2808364235 cites W2580040243 @default.
• W2808364235 cites W2588788283 @default.
• W2808364235 doi "https://doi.org/10.1080/09638288.2018.1460877" @default.
• W2808364235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29644889" @default.
• W2808364235 hasPublicationYear "2018" @default.
• W2808364235 type Work @default.
• W2808364235 sameAs 2808364235 @default.
• W2808364235 citedByCount "7" @default.
• W2808364235 countsByYear W28083642352021 @default.
• W2808364235 countsByYear W28083642352022 @default.
• W2808364235 countsByYear W28083642352023 @default.
• W2808364235 crossrefType "journal-article" @default.
• W2808364235 hasAuthorship W2808364235A5013031954 @default.
• W2808364235 hasAuthorship W2808364235A5033101354 @default.
• W2808364235 hasAuthorship W2808364235A5036105904 @default.
• W2808364235 hasAuthorship W2808364235A5040566189 @default.
• W2808364235 hasAuthorship W2808364235A5052382720 @default.
• W2808364235 hasAuthorship W2808364235A5076701726 @default.
• W2808364235 hasAuthorship W2808364235A5078267582 @default.
• W2808364235 hasAuthorship W2808364235A5084740062 @default.
• W2808364235 hasConcept C102959455 @default.
• W2808364235 hasConcept C103038586 @default.
• W2808364235 hasConcept C105795698 @default.
• W2808364235 hasConcept C120863210 @default.
• W2808364235 hasConcept C121608353 @default.
• W2808364235 hasConcept C126322002 @default.
• W2808364235 hasConcept C147583825 @default.
• W2808364235 hasConcept C153396756 @default.
• W2808364235 hasConcept C1862650 @default.
• W2808364235 hasConcept C2776166826 @default.
• W2808364235 hasConcept C2777188771 @default.
• W2808364235 hasConcept C2777861855 @default.
• W2808364235 hasConcept C2778504769 @default.
• W2808364235 hasConcept C3019424981 @default.
• W2808364235 hasConcept C33923547 @default.
• W2808364235 hasConcept C530470458 @default.
• W2808364235 hasConcept C71924100 @default.
• W2808364235 hasConcept C99476002 @default.
• W2808364235 hasConceptScore W2808364235C102959455 @default.
• W2808364235 hasConceptScore W2808364235C103038586 @default.
• W2808364235 hasConceptScore W2808364235C105795698 @default.
• W2808364235 hasConceptScore W2808364235C120863210 @default.
• W2808364235 hasConceptScore W2808364235C121608353 @default.
• W2808364235 hasConceptScore W2808364235C126322002 @default.
• W2808364235 hasConceptScore W2808364235C147583825 @default.
• W2808364235 hasConceptScore W2808364235C153396756 @default.
• W2808364235 hasConceptScore W2808364235C1862650 @default.
• W2808364235 hasConceptScore W2808364235C2776166826 @default.
• W2808364235 hasConceptScore W2808364235C2777188771 @default.

• next